Abstract: The present invention provides an oral pharmaceutical composition for treating insomnia, comprising lemborexant or a pharmaceutically acceptable salt thereof, wherein a normal dose of the lemborexant or pharmaceutically acceptable salt thereof is 5 to 10 mg per day, provided that a dose of the lemborexant or pharmaceutically acceptable salt thereof is 2.5 mg per day when the pharmaceutical composition is administered to a patient together with the agent capable of moderately or strongly inhibiting CYP3A, and/or a dose of the lemborexant or pharmaceutically acceptable salt thereof is 5 mg per day when the pharmaceutical composition is administered to the patient together with the agent capable of weakly inhibiting CYP3A.

Abstract: An examination of microwave oven-resistant sheets for heat-insulating foamed paper containers revealed that blisters occur in the containers in the course of microwave oven treatment. That is to say, the present invention addresses the problem of providing a sheet for heat-insulating foamed paper container such that no blisters occur during microwave oven treatment. The present inventors have found that the problem to be solved by the present invention can be solved by a method for producing a sheet for a heat-insulating foamed paper container, wherein an air gap of 150 mm or larger, a drawing speed of 65 m/minute or lower, and a polyethylene resin density of 923 to 930 kg/m3.

Abstract: A compound selected from the group consisting of compounds represented by the formulas below or pharmaceutically acceptable salt thereof is useful in PET imaging for AMPA receptor.